Drug classification for patients with comorbidities

References

• Pazan F, Weiss C, Wehling M,et al. The EURO-FORTA (Fit fOR The Aged) list: international consensus validation of a clinical tool for improved drug treatment in older people. Drugs Aging. 2018;35(1):61–71. https://doi.org/10.1007/s40266-017-0514-2.
   PubMed Web of Science ®Google Scholar
• Villanueva C, Albillos A, Genesca J,et al. Beta blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial. The Lancet. 2019;10181:1597–1608. https://doi.org/10.1016/S0140-6736(18)31875-0.
   Google Scholar
• Shi KQ, Liu WY, Pan ZZ,et al. Secondary prophylaxis of variceal bleeding for cirrhotic patients: a multiple-treatments meta-analysis. Eur J Clin Invest. 2013;43(8):844–854. https://doi.org/10.1111/eci.12115.
   PubMed Web of Science ®Google Scholar
• Bihari D, Westaby D, Gimson A,et al. Reductions in portal pressure by selective beta 2-adrenoceptor blockade in patients with cirrhosis and portal hypertension. Br J Clin Pharmacol. 1984;17(6):753–757.
   PubMed Web of Science ®Google Scholar
• Kim RG, Loomba R, Prokop LJ, Singh S. Statin use and risk of cirrhosis and related complications in patients with chronic liver diseases: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2017;15(10):1521–1530.e8. https://doi.org/10.1016/j.cgh.2017.04.039.
   PubMed Web of Science ®Google Scholar
• Gu Y, Yang X, Liang H, Li D. Comprehensive evaluation of effects and safety of statin on the progression of liver cirrhosis: a systematic review and meta-analysis. BMC Gastroenterol. 2019;19(1):231. https://doi.org/10.1186/s12876-019-1147-1.
   PubMed Web of Science ®Google Scholar
• Steffel J, Collins R, Antz M,et al. European heart rhythm association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Europace. 2021;23:1612–1676. https://doi.org/10.1093/europace/euab065.
   PubMed Web of Science ®Google Scholar
• Kubitza D, Roth A, Becka M,et al. Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol. 2013;76(1):89–98. https://doi.org/10.1111/bcp.12054.
   PubMed Web of Science ®Google Scholar
• Honig A, Kuyper AM, Schene AH,et al. Treatment of post-myocardial infarction depressive disorder: a randomized, placebo-controlled trial with mirtazapine. Psychosom Med. 2007;69(7):606–613. https://doi.org/10.1097/PSY.0b013e31814b260d.
   PubMed Web of Science ®Google Scholar
• Zuidersma M, Conradi HJ, van Melle JP,et al. Depression treatment after myocardial infarction and long-term risk of subsequent cardiovascular events and mortality: a randomized controlled trial. J Psychosom Res. 2013;74(1):25–33. https://doi.org/10.1016/j.jpsychores.2012.08.015.
   PubMed Web of Science ®Google Scholar
• Kim J-M, Kang H-J, Bae K-Y,et al. Determinants and escitalopram treatment effects on suicidal ideation in patients with acute coronary syndrome: findings from the K-DEPACS and EsDEPACS studies. Int J Cardiol. 2016;219:225–230. https://doi.org/10.1016/j.ijcard.2016.06.048.
   PubMed Web of Science ®Google Scholar
• Hanash JA, Hansen BH, Hansen JF,et al. Cardiovascular safety of one-year escitalopram therapy in clinically nondepressed patients with acute coronary syndrome. J Cardiovasc Pharmacol. 2012;60(4):397–405. https://doi.org/10.1097/FJC.0b013e3182677041.
   PubMed Web of Science ®Google Scholar
• Gjestad C, Westin AA, Skogvoll E, Spigset O. Effect of proton pump inhibitors on the serum concentrations of the selective serotonin reuptake inhibitors citalopram, escitalopram, and sertraline. Ther Drug Monit. 2015;37(1):90–97. https://doi.org/10.1097/FTD.0000000000000101.
   PubMed Web of Science ®Google Scholar
• Kim J, Stewart R, Lee Y,et al. Effect of escitalopram vs placebo treatment for depression on long-term cardiac outcomes in patients with acute coronary syndrome. A randomized clinical trial. JAMA. 2018;320(4):350–358. https://doi.org/10.1016/j.phrs.2016.08.017.
   PubMed Web of Science ®Google Scholar
• Laporte S, Chapelle C, Caillet P,et al. Bleeding risk under selective serotonin reuptake inhibitor (SSRI) antidepressants: a meta-analysis of observational studies. Pharmacol Res. 2017;118:19–32. https://doi.org/10.1016/j.phrs.2016.08.017.
   PubMed Web of Science ®Google Scholar
• Nochaiwong S, Ruengorn C, Awiphan R,et al. Use of serotonin reuptake inhibitor antidepressants and the risk of bleeding complications in patients on anticoagulant or antiplatelet agents: a systematic review and meta-analysis. Ann Med. 2022;54(1):80–97. https://doi.org/10.1080/07853890.2021.2017474.
   PubMed Web of Science ®Google Scholar
• Johnson EM, Whyte E, Mulsant BH,et al. Cardiovascular changes associated with venlafaxine in the treatment of late-life depression. Am J Geriatr Psychiatry. 2006;14(9):796–802. https://doi.org/10.1097/01.JGP.0000204328.50105.b3.
   PubMed Web of Science ®Google Scholar
• Zivkovic S, Koh CH, Kaza N, Jackson CA. Antipsychotic drug use and risk of stroke and myocardial infarction: a systematic review and meta-analysis. BMC Psychiatry. 2019;19(1):189. https://doi.org/10.1186/s12888-019-2177-5.
   PubMedGoogle Scholar
• Yu ZH, Jiang HY, Shao L,et al. Use of antipsychotics and risk of myocardial infarction: a systematic review and meta-analysis. Br J Clin Pharmacol. 2016;82(3):624–632. https://doi.org/10.1111/bcp.12985.
   PubMed Web of Science ®Google Scholar
• Salvo F, Pariente A, Shakir S,et al. Sudden cardiac and sudden unexpected death related to antipsychotics: a meta-analysis of observational studies. Clin Pharmacol Ther. 2016;99(3):306–314. https://doi.org/10.1002/cpt.250.
   PubMed Web of Science ®Google Scholar
• Wu CS, Tsai YT, Tsai HJ. Antipsychotic drugs and the risk of ventricular arrhythmia and/or sudden cardiac death: a nation-wide case-crossover study. J Am Heart Assoc. 2015. https://doi.org/10.1161/JAHA.114.001568.
   Web of Science ®Google Scholar